Biohit is Finnish public company whose B-shares (BIOVB) have been quoted on the Helsinki Exchanges since June 1999.

Biohit focuses on the research, development, production, and marketing of products (e.g. GastroView, GastroPanel, Quick Tests) for the screening, prevention, and diagnosis of diseases of the gastrointestinal tract. Biohit’s products are used in hospitals and laboratories around the world.

The company’s diagnostic products are combined with instruments and related software to offer comprehensive analysis systems for research and clinical diagnostics.

Biohit’s production facilities are located in Kajaani and Helsinki in Finland. The sales and marketing subsidiaries are located in France, Germany, China, Japan, Russia, the U.K. and the U.S.

GastroView is one of Biohit’s new products targeted at both medical professionals and the consumer. With a simple finger prick test a person who has a concern over the condition of his/her stomach or gastrointestinal tract can obtain much more information and therefore be able to make more rational decisions on the next course of action.